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DOI 10.1016/j.cmet.2011.02.012SUMMARY stasis? A classic distinction in the latter topic is between organsRecent studies revealed a surprising regenerative
capacity of insulin-producing b cells in mice, sug-
gesting that regenerative therapy for human diabetes
could in principle be achieved. Physiologic b cell
regeneration under stressed conditions relies on
accelerated proliferation of surviving b cells, but the
factors that trigger and control this response remain
unclear. Using islet transplantation experiments, we
show that b cell mass is controlled systemically
rather than by local factors such as tissue damage.
Chronic changes in b cell glucosemetabolism, rather
than blood glucose levels per se, are the main
positive regulator of basal and compensatory b cell
proliferation in vivo. Intracellularly, genetic and
pharmacologic manipulations reveal that glucose
induces b cell replication via metabolism by
glucokinase, the first step of glycolysis, followed by
closure of KATP channels and membrane depolariza-
tion. Our data provide a molecular mechanism for
homeostatic control of b cell mass by metabolic
demand.
INTRODUCTION
The fundamental problem of organ size control can be divided
into (1) what are the cellular origins of a given organ (i.e., stem
cells versus differentiated cells that retain a replicative potential),
and (2) what are the signals that determine organ size homeo-440 Cell Metabolism 13, 440–449, April 6, 2011 ª2011 Elsevier Inc.that are controlled by systemic factors, and organs that are
controlled by local signals (Conlon and Raff, 1999).
Insulin-producing b cells of the endocrine pancreas operate to
maintain blood glucose levels within a narrow range by secreting
insulin in response to glucose. Insufficient functional b cell mass
is the underlying cause of type 1 and amajor contributor to type 2
diabetes, underscoring the importance of understanding b cell
dynamics (Butler et al., 2003; Muoio and Newgard, 2008). In
healthy adult mice, as well as in mice recovering from a diabeto-
genic injury, new b cells are derived by replication of pre-existing
b cells (Brennand et al., 2007; Dor et al., 2004; Georgia and
Bhushan, 2004; Meier et al., 2008; Nir et al., 2007; Teta et al.,
2007). This situation implies that signals controlling b cell number
must act by modulating the survival and/or proliferation of differ-
entiated b cells.
Although it has been known for decades that food intake or
glucose infusion increases b cell replication in mice (Alonso
et al., 2007; Bonner-Weir et al., 1989; Chick, 1973; Chick and
Like, 1971) and that insulin resistance states result in a compen-
satory increase in b cell mass (Kulkarni et al., 2004), the precise
mechanisms regulating these processes are still controversial
(Butler et al., 2007; Heit et al., 2006), as emphasized by recent
reviews (Halban et al., 2010; Martens and Pipeleers, 2009; Sach-
deva and Stoffers, 2009). Specifically, controversy persists as to
the relative importance of local versus systemic signals, the latter
of which can be neural or circulating (Imai et al., 2008). There is
evidence that circulating factors control b cell proliferation,
including the observation of b cell hyperplasia in mice lacking
insulin receptors in the liver (Imai et al., 2008; Kulkarni et al.,
2004; Michael et al., 2000; Okada et al., 2007), and the demon-
stration that a circulating factor in insulin resistant animals
induces b cell proliferation in islet grafts (Flier et al., 2001).
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Glucose is a particularly attractive candidate since it can
increase the rate of b cell proliferation in vitro (Kwon et al.,
2004) and during short periods of glucose infusion in rodents
(Alonso et al., 2007; Bonner-Weir et al., 1989; Paris et al.,
2003). However, insulin, fatty acids, and incretin hormones
have also been proposed, particularly for situations of insulin
resistance where circulating glucose levels are not measurably
elevated. Furthermore, in situations of b cell destruction, such
as seen in type 1 diabetes, local inflammatory responses could
in theory be negative or positive regulators of regeneration (Duf-
field et al., 2005; Ehses et al., 2007; Tessem et al., 2008).
Here we examine the mechanisms regulating b cell prolifera-
tion in vivo, using a combination of surgical, pharmacologic,
and genetic approaches. We find that basal as well as compen-
satory b cell proliferation rates are controlled to a large extent
systemically, and that b cell glucosemetabolism is a key positive
regulator of the process. We then demonstrate that the mito-
genic effect of glycolysis is transmitted by modulation of ATP-
sensitive potassium channels. These findings may have impor-
tant therapeutic implications in both type 1 and type 2 diabetes.
RESULTS
Functional b Cell Mass Controls b Cell Proliferation
Islet Transplantation Reduces Basal and Compensatory
Proliferation of Endogenous b Cells
We have previously developed a transgenic mouse system for
conditional ablation of b cells, based on doxycycline-induced
diphtheria toxin expression in Insulin-rtTA;TET-DTA (bDTA)
mice (Nir et al., 2007). Using this systemwe showed that ablation
of80% of b cells in adult mice, resulting in diabetes, is followed
by a slow (6 weeks) return to normoglycemia and regeneration
of b cell mass, due to increased proliferation of surviving b cells
(Nir et al., 2007). To determine if this compensatory proliferation
persists in the absence of hyperglycemia, we used islet trans-
plantation to normalize blood glucose in diabetic bDTA mice.
We transplanted 500 wild-type islets under the kidney capsule
of transgenic mice and 3 weeks later added doxycycline to the
drinking water for 1 week to kill endogenous b cells. In the pres-
ence of wild-type islet grafts, mice showed normal glucose toler-
ance and normal serum insulin levels in the fasting state and
following glucose challenge (see Figure S1 available online). As
expected, apoptotic b cells were found in endogenous islets at
a frequency similar to transgenic mice bearing no grafts, and
the architecture of islets was disrupted as previously described
(Figure S1). Thus, islet transplantation uncouples transgene-
mediated pancreatic b cell ablation from the physiological
outcome of hyperglycemia.
Hyperglycemic bDTA transgenic mice showed an approxi-
mately 6-fold increase in endogenous b cell proliferation rate
7 days after the addition of doxycycline (Figure 1A). Strikingly,
the rate of b cell proliferation in transgenic mice grafted with
normal islets was 50% lower than that in transgenic, hypergly-
cemic bDTA mice bearing no grafts. Interestingly, we observed
that wild-type mice transplanted with wild-type islets had
a similar decrease in endogenous b cell proliferation, to about
50% of their basal rate of proliferation (Figure 1A), without any
change in blood glucose level (Figure S1). These results provideCclear evidence for systemic control of both basal and compensa-
tory b cell proliferation. Furthermore, while blood glucose is a key
driver of b cell proliferation (see below), the results suggest that
adaptive proliferation of b cells does not require overt hyper- or
hypoglycemia.
b Cell Proliferation in Transplanted Islets Correlates
with Functional b Cell Mass
Despite the glucose-normalizing effect of islet grafts, endoge-
nous b cells in bDTA mice bearing islet grafts had a replication
rate almost 3-fold higher than normal (Figure 1A). This could
reflect local cues for replication (e.g., destruction of islet archi-
tecture) or suboptimal b cell mass in these mice. To distinguish
between these possibilities, we examined b cell replication in
islet transplants. Grafted wild-type b cells had a higher replica-
tion rate in bDTA hosts compared with wild-type hosts (Fig-
ure 1A). This supports the concept that systemic factors, rather
than local tissue damage, are responsible for compensatory
b cell replication in bDTA mice.
To gain more insight into the control of compensatory b cell
proliferation, and to exclude the influence of local, pancreatic
factors, we performed reciprocal experiments where transgenic
bDTA islets were transplanted under the kidney capsule of wild-
type mice. As expected, the administration of doxycycline
caused extensive destruction of grafted bDTA islets, but no
hyperglycemia was observed due to the presence of a normal
complement of endogenous b cells (Figure S2). As shown in Fig-
ure 1B, the rate of b cell proliferation in grafted bDTA islets was
higher than in graftedwild-type islets. To determine if this reflects
a systemic or a local trigger, we examined b cell proliferation in
the pancreas of recipients (wild-type in both cases). Strikingly,
endogenous b cell replication rate was higher in recipients of
bDTA islets than in recipients of wild-type islets. These results
further support the idea that systemic factors control b cell prolif-
eration. Since grafted islets are not innervated, systemic regula-
tion is likely blood-borne.
These experiments suggest, but do not prove, that grafted
islets reduce b cell proliferation in the pancreas indirectly, by
secreting insulin which maintains net peripheral glucose uptake,
while reducing theworkload on host b cells without ameasurable
perturbation of circulating glucose levels. To examine this
notion, we used islets from insulin-CreER; Rosa26-loxP-stop-
loxP-Kir6.2-V59M mice (bKir). Upon tamoxifen injection, bKir
b cells express a mutant Kir6.2 subunit of the KATP channel,
which prevents glucose-induced membrane depolarization and
insulin secretion (Girard et al., 2009). If grafted islets reduce
endogenous b cell proliferation by the (indirect) action of
secreted insulin, then dysfunctional bKir islets should fail to
impact replication. Tamoxifen injection of NOD/SCIDmice trans-
planted with 500–700 bKir islets caused transient hypergly-
cemia, likely because a considerable portion of islet mass in
these mice suddenly became dysfunctional (Figure S2). Fig-
ure 1C shows that endogenous b cell replication in hosts of
bKir islets was higher than in hosts of wild-type islets. This result
strongly supports the idea that it is the secretion of insulin from
grafted islets that reduces b cell replication in the pancreas by
decreasing the workload on endogenous b cells (see below).
Relationship of Blood Glucose to b Cell Proliferation
To obtain independent evidence regarding the impact of glucose
metabolism on b cell regeneration, we plotted b cell proliferationell Metabolism 13, 440–449, April 6, 2011 ª2011 Elsevier Inc. 441
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Figure 1. Islet Transplantation Shows Systemic Regulation of Compensatory and Basal b Cell Replication and a Positive Effect of Glucose
(A) bDTA mice grafted with wild-type islets. Top, schematic of experiment (left) and expected blood glucose levels after the addition of doxycycline and b cell
ablation (right). Circles, native pancreas; ovals, transplanted islets; blue, wild-type; red, bDTA. Bottom, b cell replication in the pancreas (left) and in grafts (right).
Table under graph provides estimated numbers of islets per mouse. Error bars represent standard error.
(B) Wild-type mice engrafted with wild-type and bDTA islets. Top, schematic of experiment. Bottom, b cell replication in the pancreas (left) and in grafts (right).
Table under graph provides estimated numbers of islets per mouse. Error bars represent standard error.
(C) Wild-type mice engrafted with bKir islets (yellow before tamoxifen-induced expression, red after tamoxifen). Left, schematic of experiment. Right, b cell
replication in the pancreas. Error bars represent standard error.
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Figure 2. Relationship between Blood Glucose and b Cell Replication Rate
(A) b cell replication rate as a function of blood glucose levels at sacrifice. Open symbols, wild-type mice; closed symbols, bDTA mice. Note a positive effect of
glucose on replication rate, but no relationship between glucose levels and b cell replication rate within the transgenic group.
(B) Proposed model for the effect of glucose, via workload of b cells, on b cell replication rate. The model explains how different normoglycemic conditions may
cause different b cell replication rates.
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Glycolysis Control of b Cell Regeneration and Massas a function of blood glucose measured at sacrifice in wild-type
and bDTA mice. As previously reported, b cell replication was
higher in bDTA mice than in littermate controls (Nir et al., 2007)
(Figure 2A). Surprisingly, within the bDTA group there was no
correlation between the level of blood glucose and the rate of
proliferation. Rather, bDTA mice had an 3-fold increase in
b cell replication rate regardless of glucose levels, and even
when circulating glucose levels were within the normal range,
suggesting that even when b cell destruction is too mild to cause
overt hyperglycemia, maximal compensatory b cell proliferation
is triggered.
Working Hypothesis: Proliferation Is Regulated
by b Cell Glycolytic Flux
To explain the results presented above, we hypothesized that
b cell replication is controlled by the workload imposed on an
individual b cell in order to maintain euglycemia, as predicted
by control theory in a feedback-regulated system (Astrom and
Murray, 2009). We further hypothesized that this workload (i.e.,
insulin secretory demand) is sensed by the b cell as the rate of
glycolysis (Figure 2B). In such a system, glucose oscillations
entrain insulin secretion oscillations, which in turn regulate
peripheral glucose utilization, and thus circulating glucose levels
(Palumbo and De Gaetano, 2010). The net insulin secretion per
b cell, as regulated by glucose metabolism, is the b cell ‘‘work-
load.’’ According to this model, when the total body insulin
requirement remains constant, any reduction of b cell mass will
increase the workload on each remaining b cell and as a result
will trigger a compensatory proliferation. If b cell loss is small,
enhanced insulin secretion will prevent a measurable increase
in blood glucose level, but proliferation will nevertheless be stim-
ulated. When b cell loss reaches the point of causing hypergly-
cemia, b cell replication rate is presumably stimulatedmaximally,
hence a further rise in glucose level does not increase replication.
In the other direction, an excess of functional b cells (as in wild-
type mice bearing islet grafts) would lead to a reduced glycolytic
flux per b cell, and thereby a reduced replication rate.CThismodel explains how a homeostatic response to b cell defi-
ciency or excess can be mounted before detectable hypergly-
cemia or hypoglycemia develops.
Glucokinase Controls b Cell Function, Proliferation,
and Survival
Glucose Metabolism Is Required for Stimulation
of b Cell Proliferation
To directly examine the hypothesis that glucose triggers b cell
proliferation via glycolysis, and not, for example, via protein
glycosylation, we deleted glucokinase (GCK) in b cells of adult
mice. GCK catalyzes the rate-limiting step of glucose metabo-
lism in b cells, and is a central regulator of glucose-stimulated
insulin secretion. Its absence is expected to reduce glucose
flux in b cells and as a consequence reduce insulin secretion
and increase blood glucose levels (Magnuson et al., 2003).
Thus, GCK deficiency in b cells uncouples extracellular glucose
levels from intracellular metabolic flux. Previous genetic studies
of GCK used either heterozygous mice in which one copy of the
gene remains intact and deficiency is not b cell specific, or
a b cell-specific deletion which led to early postnatal lethality,
precluding detailed analysis (Postic et al., 1999; Terauchi et al.,
2007). To overcome these limitations, we employed a tamox-
ifen-inducible deletion of GCK specifically in b cells of adult
mice. Tamoxifen injection of adult insulin-CreER;GCKloxP/loxP
mice (bGCK) led to a 3-fold decrease in islet GCK mRNA levels,
indicating efficient deletion of the gene (data not shown). Tamox-
ifen-treated bGCK mice developed severe hyperglycemia and
hypoinsulinemia (Figure 3A), consistent with the inability of
mutant b cells to sense glucose and secrete insulin. Staining
for phospho-AMPK, a sensitive marker of cellular energy stress
(high AMP/ATP ratio) (Hardie et al., 2006) showed a striking
increase in the intensity of p-AMPK in bGCK islets (Figure 3B).
These data are consistent with energy stress and reduced
glucose flux in mutant b cells. We conclude that while bGCK
mice exhibit circulating hyperglycemia, their b cells behave as
if exposed to hypoglycemia, reflecting the blunted glycolytic flux.ell Metabolism 13, 440–449, April 6, 2011 ª2011 Elsevier Inc. 443
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Figure 3. Deletion of Glucokinase in Adult b Cells
Reduces b Cell Replication Rate
(A) Blood glucose (left) and serum insulin levels (right)
9 days after tamoxifen injection of insulin-CreER;
GCKlox/lox mice (bGCK, red) or GCKlox/lox controls (blue).
Measurements were taken in the fed state. Error bars
represent standard error.
(B) Increased phosphorylation of AMPK in bGCK islets,
9 days after tamoxifen injection, providing evidence for low
intracellular energy charge despite high blood glucose
levels. Original magnification, 8003.
(C) Reduced b cell replication rate in bGCK islets, 9 days
after tamoxifen injection. Error bars represent standard
error.
Cell Metabolism
Glycolysis Control of b Cell Regeneration and MassStaining for Ki67 revealed a dramatic drop in b cell proliferation
rate in bGCK islets (Figure 3C). This indicates that the mitogenic
effect of glucose is mediated by glucose metabolism, and that
glucose flux is a key regulator of basal b cell proliferation. We
also observed increased b cell apoptosis in bGCK mice (Fig-
ure S3), and reduced b cell size (data not shown). As a result of
these changes, total b cell mass was reduced 2-fold 2 months
after GCK deletion (Figure S3). Since the dependence of b cell
proliferation on GCK could simply reflect the minimum cellular
energy requirements for replication, we performed additional
experiments (see below), which suggest that this is not the
case and support the hypothesis that GCK, via its control of
glycolysis in b cells, is a major determinant of b cell proliferation.
Glucokinase Activation Boosts b Cell Proliferation
If suppressed b cell proliferation after GCK ablation were simply
the result of cellular starvation, enhancing the activity of GCK
above normal in wild-type animals would not be expected to
affect the b cell proliferation rate. If, however, GCK controls
proliferation by regulating the rate of glycolysis, similar to its
role in insulin secretion, increasing the activity of GCK would
be predicted to boost b cell proliferation. Pharmacologic activa-
tors of GCK are a novel class of drugs being developed for the
treatment of type 2 diabetes which act by increasing the glucose
affinity and maximum velocity of GCK and hence improve insulin
secretion (Matschinsky et al., 2006). As previously reported
(Grimsby et al., 2003), administration of a specific GCK activator
(GKA) to wild-type mice led to hypoglycemia, that persisted for
more than 24 hr (Figure 4A). Despite circulating hypoglycemia,
GKA is expected to increase the rate of glycolysis in b cells. To
test this prediction, we measured glucose oxidation in isolated
islets incubated in the presence of GKA in various concentra-
tions of glucose. As shown in Figure 4B, GKA significantly
increased glucose oxidation in all glucose concentrations tested.
Moreover, glucose oxidation in GKA-treated islets at 3 mM444 Cell Metabolism 13, 440–449, April 6, 2011 ª2011 Elsevier Inc.glucose was higher than oxidation in control
islets at 5 mM, showing that GKA uncouples
glycolysis from extracellular glucose. Consis-
tent with the in vitro glucose oxidation data,
mice treatedwith GKA showed reduced staining
for p-AMPK in islets, suggesting that GKA
increased energy charge in b cells in vivo
(Figure S4).
Seventeen hours after administration of GKA,
the fraction of replicating b cells had doubledas reflected in the number of Ki67+ b cells (Figure 4C), the
number of b cells that incorporated the thymidine analog BrdU
(Figure 4D, Figure S5), and staining for the mitotic marker
phophorylated histone H3 (Figure S5). When GKA was given to
bGCK mutant mice, blood glucose levels still decreased, likely
reflecting the activation of GCK in the liver or residual islet
GCK (data not shown); however, b cell proliferation remained
low (Figure 4E), indicating a cell-autonomous role of GCK in
b cell proliferation. These results show that the rate of b cell
proliferation in vivo is controlled by GCK and can be both
decreased and increased in response to altered GCK activity.
Finally, the islet transplantation experiments described above
suggested that in bDTA mice undergoing b cell regeneration,
enhanced glycolysis is responsible for increased replication.
Our model predicts that the addition of GKA, which artificially
increases Vmax of GCK, will further increase the rate of b cell
replication in hyperglycemic bDTA mice. As shown in Figure 4F,
this is indeed the case: GKA led to a moderate yet significant
increase in the rate of b cell replication in diabetic bDTA mice.
Glucokinase-Regulated b Cell Proliferation Is Mediated
by Plasma Membrane Depolarization
We next investigated how mitogenic signals are transmitted by
GCK. Glucose flux could, in principle, act directly on signaling
molecules such as AMPK. Alternatively, it could act via the
glucose sensing/insulin secretion pathway, where increased
ATP/ADP ratio closes KATP channels and causes membrane
depolarization. To examine if KATP channels are necessary for
the mitogenic signal of GCK, we treated mice simultaneously
with GKA and diazoxide, a KATP channel opener. As expected,
diazoxide led to a transient hyperglycemia (due to the prevention
of insulin secretion), which was unaffected by GKA (Figure 5A).
Importantly, diazoxide neutralized the mitogenic effect of GKA
(Figure 5A), suggesting that closure of KATP channels and depo-
larization were necessary for GCK-regulated replication.
A B
C D
E F
Figure 4. Effects of Glucokinase Activator
on b Cells In Vivo
(A) Reduced blood glucose levels following
a single oral administration of GKA (50 mg/kg) or
vehicle (DMSO) to wild-type mice. n > 10 mice in
each group. Error bars represent standard error.
(B) Increased glucose oxidation in wild-type islets
exposed to GKA at different glucose levels. Error
bars represent standard error.
(C) Increased b cell replication, measured as
fraction of Ki67+ b cells, 17 hr after administration
of GKA or vehicle (DMSO) to 6-week-old wild-type
mice. n refers to number of mice analyzed; for
each mouse, >2000 b cells were counted. Error
bars represent standard error.
(D) Increased incorporation of BrdU in b cells of
mice treated with a single dose of GKA. Error bars
represent standard error.
(E) GKA-induced b cell replication is abolished in
mice deficient for GCK in b cells (green and black
bars). NS, not significant. n = number of mice
analyzed. Error bars represent standard error.
(F) GKA moderately increases the fraction of
replicating b cells in hyperglycemic bDTA mice.
Error bars represent standard error.
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genic mice expressing a Cre-activated mutant of the KATP
channel Kir6.2 (bKir) described above. Acute activation of the
mutant channel in b cells caused hyperglycemia, and led to
a decrease in b cell proliferation rate. Furthermore, administra-
tion of GKA failed to induce proliferation in bKir mice (Figure 5B).
This supports the view that b cell replication depends on
a signaling pathway involving glucokinase and membrane depo-
larization. We then performed a reciprocal experiment, where
bGCKmice were injected with glyburide, a KATP channel blocker
that induces membrane depolarization. As expected, acute
administration of glyburide reduced blood glucose in bGCK
mice, albeit not to normal (Figure 5C). Strikingly, glyburide
acutely rescued b cell proliferation in bGCK mice (Figure 5C).
This finding strongly suggests that reduced b cell proliferation
in bGCK mutants is not simply a result of cellular energy deficit
but rather the result of reduced membrane depolarization.
However, it also demonstrates that glucose flux per se is needed
to achieve optimal proliferation, since glyburide stimulation re-
sulted in only partial recovery of replication, increasing it to the
same level found in glyburide-treated wild-typemice (Figure 5C).Cell Metabolism 13, 440–In both of these models, membrane
depolarization occurred in the face of
decreased glycolytic flux, due to GCK
deficiency in the former and ambient
hypoglycemia in the latter. We further
tested if glyburide can increase b cell
replication in the face of increased
glucose flux using the bDTA mouse
model. Acute administration of glyburide
decreased glucose levels of bDTA mice
somewhat, demonstrating that the drug
could further stimulate insulin secretion
(Figure 5D). Importantly, the frequencyof b cell replication in bDTA mice almost doubled upon injection
of glyburide, indicating that forced membrane depolarization, in
the presence of increased glycolytic flux, can further stimulate
proliferation.
All these studies were performed on 4- to 6-week-old mice, an
age that corresponds to young adulthood in man. To determine
whether GCK-induced b cell replication is age dependent, we
administered GKA to 6-month-old mice. We observed the ex-
pected age-dependent decrease in basal proliferation, but inter-
estingly, GKA administration resulted in a 2- to 3-fold increase in
proliferation in all age groups (data not shown).
DISCUSSION
Our experiments show conclusively that the basal proliferation
rate of adult b cells in vivo and their regeneration following injury
are controlled by systemic factors. Local factors, such as the
presence of dead cells or disrupted islet architecture, appear
to play only a minor role, if any. Thus, the control of b cell number
is analogous to that found for other systemically controlled
tissues such as blood (e.g., erythrocytes) (Stanger, 2008), liver449, April 6, 2011 ª2011 Elsevier Inc. 445
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Figure 5. Dependence of b Cell Replication Downstream of Glucokinase on Membrane Depolarization
(A) Left, effect of diazoxide (40 mg/kg) on blood glucose levels from injection to sacrifice 24 hr later. Right, diazoxide abolishes GKA-induced b cell replication in
wild-type mice. n = number of mice analyzed. Error bars represent standard error.
(B) Left, effect of transgenic expression of Kir6.2 V59M in adult b cells (bKir) on blood glucose levels. Right, the Kir6.2mutation reduces basal b cell replication and
abolishes GKA-induced b cell replication. Tamoxifen was injected on day 0 to activate the mutant gene. GKA and vehicle were administered on day 2. Error bars
represent standard error.
(C) Left, blood glucose levels in bGCK mutants and GCKlox/lox littermate controls in response to glyburide. Right, acute rescue of b cell replication in bGCK
mutants by glyburide (Glyb). Glyburide was given by oral gavage at 20 mg/kg. Error bars represent standard error.
(D) Left, effect of glyburide on blood glucose in diabetic bDTA mice. Right, glyburide increases the fraction of Ki67+ b cells in diabetic bDTA mice. Error bars
represent standard error.
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1999), and muscle (Conboy et al., 2005).
Our data strongly suggest that the key systemic factor control-
ling b cell replication is glucose. They further demonstrate that
the control of b cell number relies on determination of functional
b cell mass, capable of insulin secretion. Thus, the individual
b cell senses the organism’s insulin needs according to thework-
load placed on it. Grafted islets therefore reduce b cell replication
in the host pancreas indirectly, by releasing insulin, lowering the
workload on endogenous and transplanted b cells. Supporting
this view, grafted, nonfunctioning bKir islets failed to reduce
host b cell replication. Our conclusion is consistent with that of
a recent study that examined b cell replication in the setting of
autoimmunity (Pechhold et al., 2009).
This observation adds b cells to the short list of mammalian
tissues whose size is known to be controlled by a feedback
loop directly related to their function. This paradigm is classically
illustrated by erythrocytes, whose total number is controlled by
erythropoietin, a hormone that is produced when erythrocytes
fail to deliver sufficient oxygen to tissues. In the context of endo-
crine organs, thyroid homeostasis provides another classic
example of feedback control of organ size: thyrocyte replication
depends on TSH concentration, which in turn is negatively regu-
lated by thyroid hormone (serving as a sensitive indicator of
thyroid function). Finally, recent studies showed that the flux of
bile acids through the liver, serving as a signal for workload,
controls hepatocyte proliferation and liver mass homeostasis
(Huang et al., 2006).
We further show that b cell replication is controlled by the rate
of intracellular glucose metabolism, which we refer to as the
workload. Physiologically, this model explains how b cell number
can be finely adjusted according to the organism’s needs,
without deviating from the normoglycemic range.
In terms of molecular signaling, we find that glucose metabo-
lism controls b cell replication via KATP channels and membrane
depolarization. Our experiments indicate that both glycolysis
and membrane depolarization are necessary for the mitogenic
effect of glucose metabolism. This is consistent with previous
reports on glibenclamide-induced b cell proliferation (Guiot
et al., 1994).
What determines if enhanced glycolysis causes insulin secre-
tion alone, or both secretion and replication? We speculate that
the decision is temporally controlled, such that a short pulse of
glucose metabolism, as would happen after a meal, will trigger
secretion but not replication, while more persistent activation
of the pathway (indicating an organismal need for more b cells),
will trigger replication. Experiments examining this hypothesis
are ongoing.
Our results are consistent with a recent study of mice globally
heterozygous for glucokinase, which found that two copies of
GCK were necessary to achieve b cell hyperplasia in response
to high-fat diet, and identified IRS2 as a critical component in
the GCK-dependent mitogenic response to a high-fat diet (Ter-
auchi et al., 2007). However, this paper concluded that normal
levels of glucose oxidation are not necessary for compensatory
b cell replication, which is not supported by our finding that the
rate of glycolysis in b cells, even when uncoupled from blood
glucose levels, is the critical driver of basal and compensatory
b cell replication (via its effect on membrane depolarization).CWhile we have shown here that glucose is the key driver of
b cell proliferation, toxic effects of glucose on b cells are well
recognized and are thought to be important in the pathogenesis
of diabetes. What is the relationship between glucose-induced
replication and glucotoxicity? We have recently reported on
enhanced replication as well as enhanced apoptosis in b cells
of a human patient bearing an activating mutation in glucokinase
(Kassem et al., 2010). This suggests that toxic effects of glucose
are also mediated through glycolysis, like the mitogenic effects,
and shows that glucose can trigger simultaneously replication
and apoptosis. While in this clinical case, as well as in bDTA
mice, the net effect of glucose metabolism was expansion of
b cell mass, it is possible that under other settings the net effect
of glucose is different. It will be important to identify the molec-
ular pathways leading from glycolysis to b cell replication and
apoptosis and their divergence points.
Our study addresses the mechanisms that control the replica-
tion of differentiated b cells. While there is strong evidence that
replication is the major determinant of b cell mass in mice and
men, under certain circumstances b cells could be generated
from other cells (neogenesis), including differentiation of duct
cells (Inada et al., 2008; Xu et al., 2008) or reprogramming of
alpha cells (Thorel et al., 2010). It will be interesting to determine
if glucosemetabolism has a role in b cell neogenesisis or whether
entirely different pathways control this process, as occurs in
embryonic development.
Our data have several clinical implications. First, if glucose-
driven glycolysis is the key mitogenic trigger for b cells, reducing
circulating glucose levels to normal or subnormal levels by the
administration of exogenous insulinmay reduce b cell proliferation
rate due to reduced workload. While the normalization of blood
glucose in diabetic patients is clearly beneficial for the patients
and for b cell survival and function, the antimitogenic effects of
this correction may have a long-term impact on b cell mass.
Second, glucokinase activators, upcoming drugs aimed at
improving the control of blood glucose in type 2 diabetes, could
have beneficial effects on b cell number. We predict that non-
tissue-specific GKAs will be mitogenic to b cells, while liver-
specific GKAs will decrease b cell replication if they effectively
achieve euglycemiawhile decreasing demand for insulin.Whether
GKAs increaseb cell proliferation in humans remains to be proven,
but this idea is strongly supported by the observation that patients
bearinganactivatingmutation in theglucokinasegenehavehyper-
plastic islets (Cuesta-Munoz et al., 2004; Kassem et al., 2010).
In conclusion, we identify a simple mechanism for homeo-
stasis of b cell proliferation andmass. b cells adjust their prolifer-
ation rate according to the rate of glycolysis; this provides
a system for sensitive measurement of organismal demand for
b cells, while normoglycemia is maintained. The same homeo-
static mechanism appears to be responsible for the control of
b cell number during healthy adult life as well as during regener-
ation following injury. Our findings following genetic and pharma-
cologic manipulation of b cell KATP channel activity suggest that
the downstream mechanism by which glucose metabolism trig-
gers proliferation is similar to the mechanism regulating insulin
secretion. Further research is required to fully characterize this
pathway and to identify points at which novel therapeutic inter-
ventions can be developed, aimed at boosting b cell mass for
the cure of diabetes.ell Metabolism 13, 440–449, April 6, 2011 ª2011 Elsevier Inc. 447
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Transgenic Mice
Transgenic/knockout mouse strains used in this study included insulin-rtTA,
TET-DTA (bDTA) (Nir et al., 2007), insulin-CreER (Dor et al., 2004), Pdx1-CreER
(Gu et al., 2002), GCK loxP/loxP (bGCK) (Postic et al., 1999), and Rosa26-LSL-
Kir6.2 V59M (bKir) (Girard et al., 2009). The joint ethics committee (IACUC) of
the Hebrew University and Hadassah Medical Center approved the study
protocol for animal welfare. The Hebrew University is an AAALAC Interna-
tional-accredited institute.
Drugs
Mice were administered with the following drugs: glucokinase activator Ro28-
1675 (Grimsby et al., 2003), 50 mg/kg; glyburide (Sigma), 20 mg/kg; diazoxide
(Sigma), 40 mg/kg. All these drugs were dissolved in DMSO and given by oral
gavage at 10 ml/gr body weight. Doxycycline was given in the drinking water at
400 mg/ml for 7 days. Tamoxifen was dissolved in corn oil and administered
subcutaneously via a single injection of 8 mg/mouse.
Assays
Islet transplantation was performed as described before (Molano et al., 2003).
Graft recipients were C57/Bl6 males (wild-type or bDTA, Figure 1A) aged
6–7 weeks. Recipients of bDTA or bKir islets were NOD/SCID males aged
7–8 or 8–10 weeks, respectively. Comparisons of b cell replication rate were
performed between control and experimental mice of the same strain, sex,
and age. Islet donors were males aged 9–12 weeks. Donors of bDTA or bKir
islets were of the same strain, sex, and age as donors of wild-type islets in
the same experiments. Grafts were composed of 500–700 hand-picked islets.
Glucose and insulin levels were measured in the fasted state, unless stated
otherwise. The rate of glucose oxidation was determined by measuring the
formation of 14CO2 from D-[U
14C] glucose as previously described (Malaisse
et al., 1974). Briefly, isolated islets fromC57/B6mice were incubated overnight
in standard culture medium. The next day, islets were divided into batches of
40 islets and incubated in 100 ml KRBB solution containing either 3, 5, or 10mM
glucose, 0.5% w/v BSA and 0.5, 1, or 2 mCi of D-[U14C] glucose (PerkinElmer),
respectively. Incubation was performed in 0.5 ml tubes placed inside 20 ml
glass scintillation vials fitted with airtight rubber seals (Altech). An eppendorf
tube placed inside the scintillation vials contained 200 ml of hyamine (Perki-
nElmer) to absorb CO2 produced. Islets were incubated for 60 min at 37
C
with continuous shaking, with either GKA or vehicle. Metabolism was stopped
by injecting 50 ml of 3M perchloric acid into the incubation tube through the
rubber seal. After another 1 hr incubation at room temperature, the amount
of radioactive CO2 in the hyamine tube was determined by liquid scintillation
counter.
To determine b cell replication rate, at least 2000 insulin-positive cells were
counted per mouse and scored for the percentage of Ki67-positive cells.
Glucose tolerance tests, insulin measurements, immunostaining, calculation
of b cell mass, and TUNEL assays (Roche) were as described before (Nir et al.,
2007; Weinberg et al., 2007). In all statistical analyses, *p < 0.05; **p < 0.01;
***p < 0.005, NS, p > 0.05.
Antibodies
Primary antibodies used in this study included rabbit anti-Ki67 (NeoMarkers,
1:200), guinea pig anti-insulin (Dako, 1:500), mouse anti-glucagon (BCBC,
1:800), rabbit anti-p-AMPK (Cell Signaling, 1:100, requires amplification with
TSA kit, NEN), and goat anti-pdx1 (a gift fromChrisWright, 1:2500). Secondary
antibodies were from Jackson Immunoresearch.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found at doi:10.
1016/j.cmet.2011.02.012.
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